These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38138199)

  • 41. [Assessment tools for systemic lupus erythematosus].
    Aringer M; Leuchten N
    Z Rheumatol; 2023 Jun; 82(5):361-367. PubMed ID: 37188996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally.
    Yee CS; Gordon C; Isenberg DA; Griffiths B; Teh LS; Bruce IN; Ahmad Y; Rahman A; Prabu A; Akil M; McHugh N; Edwards CJ; D'Cruz D; Khamashta MA; Farewell VT
    Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1623-1630. PubMed ID: 33787088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon-α.
    Mathian A; Mouries-Martin S; Dorgham K; Devilliers H; Barnabei L; Ben Salah E; Cohen-Aubart F; Garrido Castillo L; Haroche J; Hie M; Pineton de Chambrun M; Miyara M; Sterlin D; Pha M; Lê Thi Huong D; Rieux-Laucat F; Rozenberg F; Gorochov G; Amoura Z
    Arthritis Rheumatol; 2019 May; 71(5):756-765. PubMed ID: 30507062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum and urine interleukin-17A levels as biomarkers of disease activity in systemic lupus erythematosus.
    Nordin F; Shaharir SS; Abdul Wahab A; Mustafar R; Abdul Gafor AH; Mohamed Said MS; Rajalingham S; Shah SA
    Int J Rheum Dis; 2019 Aug; 22(8):1419-1426. PubMed ID: 31179646
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation between the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 and the European Consensus Lupus Activity Measurement in juvenile systemic lupus erythematosus.
    Sato JO; Corrente JE; Saad-Magalhães C
    Lupus; 2016 Nov; 25(13):1479-1484. PubMed ID: 27230556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients.
    Wang Y; Xie J; Liu Z; Fu H; Huo Q; Gu Y; Liu Y
    Exp Ther Med; 2017 May; 13(5):2577-2583. PubMed ID: 28565882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
    Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
    Mende R; Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Lin E; Chang J; Hoi AY; Morand EF; Harris J; Lang T
    Front Immunol; 2018; 9():1250. PubMed ID: 29930551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.
    Lewandowski LB; Schanberg LE; Thielman N; Phuti A; Kalla AA; Okpechi I; Nourse P; Gajjar P; Faller G; Ambaram P; Reuter H; Spittal G; Scott C
    Lupus; 2017 Feb; 26(2):186-194. PubMed ID: 27488473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
    Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Associations between physicians' global assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus: A longitudinal study.
    Louthrenoo W; Kasitanon N; Morand E; Kandane-Rathnayake R
    Lupus; 2021 Sep; 30(10):1586-1595. PubMed ID: 34192957
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease activity and damage in hospitalized lupus patients: a Sabah perspective.
    Selvananda S; Chong YY; Thundyil RJ
    Lupus; 2020 Mar; 29(3):344-350. PubMed ID: 32046576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Chinese version of the SLEQOL is a reliable assessment of health-related quality of life in Han Chinese patients with systemic lupus erythematosus.
    Jiang HZ; Lin ZG; Li HJ; -Du Q; -Tian W; Wang SY; Guan SQ; Mei YF
    Clin Rheumatol; 2018 Jan; 37(1):151-160. PubMed ID: 29168029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores.
    Speyer CB; Li D; Guan H; Yoshida K; Stevens E; Jorge AM; Everett BM; Feldman CH; Costenbader KH
    Rheumatol Int; 2020 Feb; 40(2):257-261. PubMed ID: 31784790
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of specialty care in the management of patients with systemic lupus erythematosus.
    Urowitz MB; Kagal A; Rahman P; Gladman DD
    J Rheumatol; 2002 Jun; 29(6):1207-10. PubMed ID: 12064836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical disease activity index applicability in lupus arthropathy: Unraveling underdiagnosed joint activity.
    Moura CA; Fonseca V; Alves EM; Silva de Oliveira I; Santiago MB
    Lupus; 2023 Oct; 32(12):1402-1408. PubMed ID: 37844912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disease Activity and Rate and Severity of Flares During Peripartum Period in Thai Patients With Systemic Lupus Erythematosus: An Age at Diagnosis and Disease Duration Matched Controlled Study.
    Louthrenoo W; Trongkamolthum T; Kasitanon N; Wongthanee A
    J Clin Rheumatol; 2022 Mar; 28(2):e473-e479. PubMed ID: 34176885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.
    Niederkorn A; Frühauf J; Schwantzer G; Wutte N; Painsi C; Werner S; Stradner M; Berghold A; Hermann J; Aberer E
    Arch Dermatol Res; 2018 Aug; 310(6):485-493. PubMed ID: 29728857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.